Last updated on May 2019

Evaluation of SPN-812 ER High Dose in Children With ADHD

Brief description of study

This study will evaluate the efficacy and safety of high doses of SPN 812 ER in children with ADHD

Detailed Study Description

This is a multicenter, randomized, double-blind, placebo-controlled, 3-arm, parallel-group study, to assess the efficacy and safety of SPN-812 ER as monotherapy for the treatment of children 6-11 years old with ADHD.

Clinical Study Identifier: NCT03247543

Recruitment Status: Closed

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.